文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

退休社区耐多药宋内志贺菌暴发中阿奇霉素与环丙沙星治疗结局

Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018.
PubMed 文献 · Clin Infect Dis · 2022-01-01

2018年美国CDC与佛蒙特州卫生部调查一起退休社区耐多药宋内志贺菌暴发,共24例培养确诊病例。分离株对甲氧苄啶-磺胺甲噁唑、氨苄西林和头孢曲松耐药,对阿奇霉素和环丙沙星敏感性降低。4例接受阿奇霉素治疗者全部临床失败,其中2例微生物学失败;2例环丙沙星治疗失败。

要点

  • 耐多药宋内志贺菌对阿奇霉素敏感性降低,4例治疗全部临床失败。
  • 环丙沙星体外敏感但含gyrA突变,2例治疗失败。
  • 提示需完善药敏折点与系统结局研究以指导替代治疗。

核心结论

  • 阿奇霉素治疗失败表明临床折点对识别耐药株替代治疗方案的重要性。
  • 治疗失败凸显全面药敏试验和系统结局研究的必要性,尤其耐多药志贺菌在更广泛人群中出现。

研究设计与样本

  • 2018年美国CDC与佛蒙特州卫生部对退休社区耐多药宋内志贺菌暴发展开调查,共24例培养确诊病例。
  • 回顾住院和门诊病历评估临床与微生物学应答,临床失败定义为治疗结束后腹泻(每日≥3次稀便)持续≥1天,微生物学失败为治疗结束后粪便培养仍检出宋内志贺菌。
  • 采用肉汤微量稀释法进行药敏试验,全基因组测序鉴定耐药机制。

主要发现

  • 分离株对甲氧苄啶-磺胺甲噁唑、氨苄西林和头孢曲松耐药,对阿奇霉素和环丙沙星敏感性降低。
  • 分离株含大环内酯耐药基因mph(A)和erm(B),阿奇霉素最低抑菌浓度高于CLSI流行病学折点≤16 µg/mL。
  • 24例中4例接受阿奇霉素治疗,全部临床治疗失败,其中2例微生物学治疗失败。
  • 分离株对环丙沙星敏感但含gyrA突变,2例环丙沙星治疗失败。

关键数值与推荐

  • 阿奇霉素最低抑菌浓度高于CLSI流行病学折点≤16 µg/mL。
  • 临床失败定义为治疗结束后腹泻(每日≥3次稀便)持续≥1天。
  • 微生物学失败定义为治疗结束后粪便培养检出宋内志贺菌。

临床怎么用

  • 对耐多药宋内志贺菌感染,阿奇霉素和环丙沙星治疗可能失败,需结合药敏和基因检测选择替代方案。
  • 临床应关注治疗结束后腹泻持续或粪便培养仍阳性,及时评估治疗失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2018, the Centers for Disease Control and Prevention and the Vermont Department of Health investigated an outbreak of multidrug-resistant Shigella sonnei infections in a retirement community that offered a continuum of care from independent living through skilled nursing care. The investigation identified 24 culture-confirmed cases. Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxone, and had decreased susceptibility to azithromycin and ciprofloxacin. METHODS: To evaluate clinical and microbiologic response, we reviewed inpatient and outpatient medical records for treatment outcomes among the 24 patients with culture-confirmed S. sonnei infection. We defined clinical failure as diarrhea (≥3 loose stools per day) for ≥1 day after treatment finished, and microbiologic failure as a stool culture that yielded S. sonnei after treatment finished. We used broth microdilution to perform antimicrobial susceptibility testing, and whole genome sequencing to identify resistance mechanisms. RESULTS: Isolates contained macrolide resistance genes mph(A) and erm(B) and had azithromycin minimum inhibitory concentrations above the Clinical and Laboratory Standards Institute epidemiological cutoff value of ≤16 µg/mL. Among 24 patients with culture-confirmed Shigella infection, 4 were treated with azithromycin; all had clinical treatment failure and 2 also had microbiologic treatment failure. Isolates were susceptible to ciprofloxacin but contained a gyrA mutation; 2 patients failed treatment with ciprofloxacin. CONCLUSIONS: These azithromycin treatment failures demonstrate the importance of clinical breakpoints to aid clinicians in identifying alternative treatment options for resistant strains. Additionally, these treatment failures highlight a need for comprehensive susceptibility testing and systematic outcome studies, particularly given the emergence of multidrug-resistant Shigella among an expanding range of patient populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gharpure R, Friedman CR, Fialkowski V, et al. Azithromycin and Ciprofloxacin Treatment Outcomes During an Outbreak of Multidrug-Resistant Shigella sonnei Infections in a Retirement Community-Vermont, 2018. Clin Infect Dis. 2022. PMID: 33993224. doi:10.1093/cid/ciab450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。